Literature DB >> 7037426

Enhanced prostacyclin production by dipyridamole in man.

G G Neri Serneri, G Masotti, L Poggesi, G Galanti, A Morettini.   

Abstract

The effects of some phosphodiesterase (PDE) inhibitors (dipyridamole, theophylline, papaverine and SH-869) on prostacyclin (PGI2) production have been studied in vitro and in vivo. PGI2 was bioassayed by Vane's superfusion technique. In rabbit aortic rings, only dipyridamole in concentrations from 1 to 12 microM was able to stimulate PGI2 biosynthesis in a dose-dependent manner. This effect was also detected with so-called "exhausted" rabbit aortic rings. The other PDE inhibitors used, both in microM and mM concentration, did not affect PGI2 biosynthesis. Dipyridamole was found to increase PGI2 production in healthy volunteers, when given both by infusion (8 micrograms/kg/min x 2h) and by oral administration (375 mg/day for seven days). Circulating PGI2 and PGI2 production induced by a 3-min period of ischaemia were increased by an average of 137% (p less than 0.001) and 30.8% (p less than 0.001) respectively. Saline and theophylline (as aminophylline) infusions used as controls did not affect PGI2 production.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7037426     DOI: 10.1007/bf00609581

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  22 in total

1.  A laminar flow superfusion technique with much increased sensitivity for the detection of smooth muscle-stimulating substances.

Authors:  S H Ferreira; F De Souza Costa
Journal:  Eur J Pharmacol       Date:  1976-10       Impact factor: 4.432

2.  Circulating prostacyclin may be reduced in diabetes.

Authors:  C T Dollery; L A Friedman; C N Hensby; E Kohner; P J Lewis; M Porta; J Webster
Journal:  Lancet       Date:  1979 Dec 22-29       Impact factor: 79.321

3.  The effects of prostacyclin (PGI2) on tissues which detect prostaglandins (PG'S).

Authors:  C Omini; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1977-10

4.  Intravenous theophylline therapy: nomogram guidelines.

Authors:  W J Jusko; J R Koup; J W Vance; J J Schentag; P Kuritzky
Journal:  Ann Intern Med       Date:  1977-04       Impact factor: 25.391

5.  A sensitive radioimmunoassay for 6-keto-prostaglandin F1alpha: preliminary observations on circulating concentrations.

Authors:  M D Mitchell
Journal:  Prostaglandins Med       Date:  1978-07

6.  Effect of indomethacin on the renal actions of theophylline.

Authors:  E Oliw; E Anggård; B B Fredholm
Journal:  Eur J Pharmacol       Date:  1977-05-01       Impact factor: 4.432

7.  Dipyridamole: a potent stimulator of prostacyclin (PGI2) biosynthesis.

Authors:  K E Blass; H U Block; W Förster; K Pönicke
Journal:  Br J Pharmacol       Date:  1980-01       Impact factor: 8.739

8.  Biotransformation and cardiovascular effects of arachidonic acid in the dog.

Authors:  K M Mullane; G J Dusting; J A Salmon; S Moncada; J R Vane
Journal:  Eur J Pharmacol       Date:  1979-03-01       Impact factor: 4.432

9.  Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid.

Authors:  G J Dusting; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1977-01

10.  Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin.

Authors:  S Moncada; R Korbut
Journal:  Lancet       Date:  1978-06-17       Impact factor: 79.321

View more
  6 in total

Review 1.  Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses.

Authors:  Christopher B Pattillo; Kai Fang; Justin Terracciano; Christopher G Kevil
Journal:  Ann N Y Acad Sci       Date:  2010-10       Impact factor: 5.691

2.  Dipyridamole treatment in chronic obstructive airways disease: effect on platelet regeneration time.

Authors:  E Tremoli; L Bertoli; R Merlini; S Colli; P Maderna; O Mantero; C R Sirtori
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 3.  Targeting phosphodiesterases in anti-platelet therapy.

Authors:  Matthew T Rondina; Andrew S Weyrich
Journal:  Handb Exp Pharmacol       Date:  2012

4.  Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway.

Authors:  Prasanna K Venkatesh; Christopher B Pattillo; Billy Branch; Jay Hood; Steven Thoma; Sandra Illum; Sibile Pardue; Xinjun Teng; Rakesh P Patel; Christopher G Kevil
Journal:  Cardiovasc Res       Date:  2010-01-08       Impact factor: 10.787

Review 5.  Multifunctional actions of approved and candidate stroke drugs.

Authors:  Jens Minnerup; Wolf-Rüdiger Schäbitz
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

Review 6.  Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?

Authors:  Mauro Giorgi; Silvia Cardarelli; Federica Ragusa; Michele Saliola; Stefano Biagioni; Giancarlo Poiana; Fabio Naro; Mara Massimi
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.